Milestone Metrics for Growth-Oriented Companies

In today’s business climate, medical device and life sciences companies need to be properly positioned at each phase of development with the appropriate plans in place for later portfolio development stages. Panelists will review key business and intellectual property management tools and strategies that are needed at the early-, mid- and late-growth stages as well the types of funding needed to fuel growth throughout the product life cycle. We also will address how and when you should plan for an IPO as well as other exit strategies, including merger and acquisitions.

Topics include:

• How companies can balance the need to continually innovate while minimizing the failure rate
  
• How to realize revenue streams earlier in the process
  
• How to evaluate innovation based on potential business value

Panelists:

• Keith Lindenbaum, Partner, Foley & Lardner LLP


• David Kantaros, Partner, Foley & Lardner LLP


• Fouad Azzam, Ph.D., General Partner, Life Sciences Partners


• Jeff Barlow, Managing Director, Head of US Life Sciences Investment Banking, Canaccord Adams


• Stacy Coen, Senior Director of Business Development, Genzyme Corporation


• Robert Mashal, Ph.D., President & CEO, NKT Therapeutics Inc.